title: Case 2. Hemangioblastomas: diagnosis of von Hippel-Lindau disease and antiangiogenic treatment with SU5416.
authors.affiliation: Department of Medicine, University Hospital Hamburg-Eppendorf, University of Hamburg, Germany.
authors.forename: Gunter
authors.initials: G
authors.lastname: Schuch
authors.forename: Maike
authors.initials: M
authors.lastname: de Wit
authors.forename: Jan
authors.initials: J
authors.lastname: Höltje
authors.forename: Eckart
authors.initials: E
authors.lastname: Laack
authors.forename: Georgia
authors.initials: G
authors.lastname: Schilling
authors.forename: Dieter K
authors.initials: DK
authors.lastname: Hossfeld
authors.forename: Walter
authors.initials: W
authors.lastname: Fiedler
authors.forename: Paul
authors.initials: P
authors.lastname: Scigalla
authors.forename: Mark S
authors.initials: MS
authors.lastname: Jacobs
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D001707:Biopsy, Needle; D002528:Cerebellar Neoplasms / Q000175:diagnosis* / Q000601:surgery; D003937:Diagnosis, Differential; D005500:Follow-Up Studies; D018325:Hemangioblastoma / Q000175:diagnosis* / Q000601:surgery; D006801:Humans; D007150:Immunohistochemistry; D007211:Indoles / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000601:surgery; D011758:Pyrroles / Q000627:therapeutic use*; D018570:Risk Assessment; D016896:Treatment Outcome; D006623:von Hippel-Lindau Disease / Q000175:diagnosis* / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D007211:Indoles; D011758:Pyrroles; C116890:Semaxinib